News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘TargetedTherapy’ clear

  • Dana-Farber researchers identify new agent that resensitizes drug-resistant HER2-positive breast cancer tumors to front-line therapies in preclinical study. This discovery will lead to the launch clinical trial of the new agent in women with a metastatic form of the disease.

Tags: BreastCancer, TargetedTherapy

  • Clinical genomic sequencing is feasible in pediatric oncology and can be used to recommend therapy or pinpoint diagnosis in children with solid tumors according to research led by Dana-Farber/Boston Children's Cancer and Blood Disorders Center. The findings, published in JAMA Oncology, represent a significant step in making precision medicine available to children with cancer.

Tags: ChildhoodCancer, TargetedTherapy, Genetics

  • Dana-Farber scientists report that midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia.

Tags: TargetedTherapy, Leukemia

  • A new drug for renal cell carcinoma slowed the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had previously kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

Tags: TargetedTherapy

  • A new technology developed at Dana-Farber may make it possible to target "undruggable" proteins and overcome drug resistance by using a cancer cell's own protein-degrading machinery to destroy, not just inhibit, cancer proteins.

Tags: BasicResearch, TargetedTherapy

  • First study of the genomic composition of prostate cancer shows many patients have gene mutations that can be targeted with existing or potential drugs.

Tags: Genomics, ProstateCancer, TargetedTherapy

  • Patients whose metastatic stomach or esophageal cancers were driven by a mutated HER2 gene had markedly improved response rates and survival when bevacizumab (Avastin) was added to a standard drug combination according to a new study led by scientists at Dana-Farber Cancer Institute,

Tags: TargetedTherapy

  • Dana-Farber researchers report in the New England Journal of Medicine that ibrutinib, a newly approved drug for Waldenström's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years.

Tags: TargetedTherapy, TranslationalResearch, Lymphoma

  • Dana-Farber experts share five things you should know about precision medicine.

Tags: Genomics, TargetedTherapy

  • Dana-Farber researchers report women with small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years.

Tags: BreastCancer, TargetedTherapy

Showing 1-10 of 52 items